[{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ GSK"},{"orgOrder":0,"company":"Genmab","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Janssen Biotech"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Pfizer Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Pfizer Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Merck & Co"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teclistamab","moa":"Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Camidanlumab Tesirine","moa":"DNA | Interleukin-2 receptor alpha chain","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ ADC Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ ADC Therapeutics"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GEN3009","moa":"Leukocyte antigen CD37 (CD37)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GEN1044","moa":"Oncotrophoblast glycoprotein 5T4 (TPBG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GEN1053","moa":"CD27","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GEN1042","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":3.8999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":3.8999999999999999,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"ProfoundBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":1.8,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"ProfoundBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":1.8,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GEN3014","moa":"CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GEN1047","moa":"CD3 \/ CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GEN1055","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"GEN1042","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BNT314","moa":"4-1BB\/EpCAM","graph1":"Oncology","graph2":"Phase I","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"6","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GEN1056","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GEN1057","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genmab","amount2":0.41999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"4","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Scancell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genmab","amount2":0.63,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.63,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"4","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Bolt Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genmab","amount2":0.88,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.88,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"3","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Argenx","highestDevelopmentStatusID":"2","companyTruncated":"Genmab \/ Argenx"},{"orgOrder":0,"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Genmab \/ Tavotek Biotherapeutics"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ GSK"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":3.8999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":3.8999999999999999,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ AbbVie Inc | Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ AbbVie Inc | Eli Lilly"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GEN3017","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Undisclosed","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"1","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Tubulin | Coagulation factor III","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Acasunlimab","moa":"||4-1BB\/PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"InSysBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"RUSSIA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"GEN1042","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enapotamab Vedotin","moa":"Tubulin | Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GEN1107","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GEN1286","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GEN1078","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Oxford Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"OBT700","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"5","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Expanded Collaboration","leadProduct":"BNT313","moa":"CD27","graph1":"Oncology","graph2":"Preclinical","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"4-1BB|PDL1","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"BNT314","moa":"4-1BB|EpCAM","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Genmab"},{"orgOrder":0,"company":"Genmab","sponsor":"Zulfa Omer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Zulfa Omer","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Zulfa Omer"}]

Find Clinical Drug Pipeline Developments & Deals by Genmab

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : Epcoritamab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          August 07, 2025

                          Lead Product(s) : Epcoritamab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Zulfa Omer

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : BNT314 is a Antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Colorectal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 23, 2025

                          Lead Product(s) : BNT314

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : BioNTech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : Acasunlimab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Melanoma, Cutaneous Malignant.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 22, 2025

                          Lead Product(s) : Acasunlimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : Epkinly (epcoritamab) is a bispecific CD20/CD3 T-cell engager therapy being investigated for adult patients with relapsed/refractory follicular lymphoma in combination with rituximab and lenalidomide.

                          Product Name : Epkinly

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 01, 2025

                          Lead Product(s) : Epcoritamab,Lenalidomide,Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Tivdak

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 01, 2025

                          Lead Product(s) : Tisotumab Vedotin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Recipient : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : Tivdak (tisotumab vedotin) is an antibody-drug conjugate that acts as coagulation factor III binding agent & tubulin inhibitor. It is approved for the treatment of cervical cancer.

                          Product Name : Tivdak

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          March 31, 2025

                          Lead Product(s) : Tisotumab Vedotin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : Rina-S (rinatabart sesutecan) is an investigational FRα-targeted, Topo1 ADC, which is being evaluated for FR alpha-expressing ovarian cancer, endometrial cancer, primary peritoneal carcinoma.

                          Product Name : Rina-S

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : Rinatabart Sesutecan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : Epkinly (epcoritamab) is an IgG1-bispecific antibody, which is approved for the treatment of relapsed/refractory follicular lymphoma. It is designed to direct cytotoxic T cells selectively.

                          Product Name : Epkinly

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : Epcoritamab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 06, 2025

                          Lead Product(s) : Epcoritamab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Massachusetts General Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 13, 2025

                          Lead Product(s) : GEN1078

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank